Dyno Therapeutics

Cambridge, United States Founded: 2018 • Age: 8 yrs
AI-based AAV engineering for gene therapy delivery is provided.

About Dyno Therapeutics

Dyno Therapeutics is a Healthcare company based in Cambridge (United States) founded in 2018. AI-based AAV engineering for gene therapy delivery is provided. Dyno Therapeutics has raised $109 million across 2 funding rounds from investors including Andreessen Horowitz, Casdin Capital and Google Ventures. The company has 38 employees. Its website dynotx.com draws about 14 thousand monthly visits. Dyno Therapeutics offers products and services including bCap 1, eCap 1, and Platform. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its competitors include BridgeBio, Spark Therapeutics and Alnylam; 3 of its 3 listed competitors have raised funding.

Company details

Founded in 2018 and based in Cambridge, United States, operations in the biotechnology sector are focused on AAV engineering through AI and data-driven methods. Vectors are developed for safe, targeted in vivo gene therapy delivery. Next-generation DNA synthesis of AAV capsids is combined with high-throughput sequencing and machine learning. Relationships between capsid sequences and functions are mapped, while vectors are optimized for enhanced therapeutic outcomes.

  • Headquarters Cambridge, United States
  • Employees 38
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Website dynotx.com
  • Social LinkedIn X
Key Metrics
  • Total Equity Funding
    $109M (USD)

    in 2 rounds

  • Latest Funding Round
    $100M (USD), Series A

    May 2021

  • Investors
  • Employee Count
    38

Products & Services of Dyno Therapeutics

Dyno Therapeutics offers a comprehensive portfolio of products and services, including bCap 1, eCap 1, and Platform.

bCap 1
Gene Therapy Vector

AI-designed vector for targeted gene delivery in therapies

eCap 1
Gene Therapy Vector

AI-powered vector for enhanced gene therapy applications

Platform
AI Development Tool

System for discovering novel gene therapy vectors using AI

Funding Insights of Dyno Therapeutics

Dyno Therapeutics has successfully raised a total of $109M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $100 million completed in May 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $109M
  • Total Rounds 2
  • Last Round Series A β€” $100M
  • First Round $9M

    (May 2020)

  • Investors Count 8

All 2 funding rounds of Dyno Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
May 2021$100MSeries A–a16z
May 2020$9MSeed–Polaris Partners, CRV
–
Valuation history

8 investors in total: 8 institutional.

Investors in Dyno Therapeutics

Dyno Therapeutics has secured backing from 8 investors, including venture fund investors. Prominent investors backing the company include Andreessen Horowitz, Casdin Capital and Google Ventures.

All
Venture Fund
InvestorDescriptionFounded YearDomainLocation
Venture capital investments in technology sectors are handled by Andreessen Horowitz.
a16z.com
Investing in Life Sciences sectors like Healthcare and Biotechnology.
casdincapital.com
Corporate backed venture capital fund investing in multiple sectors
gv.comMountain View, United States
Provider of venture capital investments across planetary, human, and economic health
obvious.comSan Francisco, United States
Seed and early-stage technology companies are funded by Lux Capital.
luxcapital.comMenlo Park, United States
Early-stage investments are made in frontier science ventures.
kdtvc.comBlack Mountain, United States
CRV is recognized as a venture capital firm investing in technology startups.
crv.comPalo Alto, United States
US focused venture capital firm
polarispartners.comBoston, United States
Premium access

Investor details for Dyno Therapeutics

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Dyno Therapeutics

62 people are tracked at Dyno Therapeutics (10 in leadership, 6 in board & advisors, 46 in team); the tracked headcount is 38.

NameRoleGroup
Eric Kelsic
CEO & Co-FounderLeadership
Tyson Bertmaring
VP, Head of StewardshipLeadership
Yvette Leung
VP, Business DevelopmentLeadership
Kosta Kleitsas
VP, Head of PeopleLeadership
David Levy-Booth
Associate DirectorLeadership
Sam Sinai
VP, Deep Learning Research & Co-FounderLeadership
Russ Katz
Manager, Chief of StaffLeadership
Rebecca Servais
Director, OperationsLeadership
Daniela Pignatta
Director, Experimental ScienceLeadership
Carrie Adams
Associate People DirectorLeadership
Tomas Bjorklund
Scientific Co-founder & Scientific AdvisorBoard & advisors
Debora S. Marks
Scientific AdvisorBoard & advisors
Nicole Paulk
Scientific AdvisorBoard & advisors
Alan Crane
Co-Founder & Executive ChairmanBoard & advisors
Adrian Veres
SVP, Experimental Science & Co-FounderBoard & advisors
George Church
Scientific Co-founder & Scientific AdvisorBoard & advisors
Carey Twynman
Senior Talent Acquisition Specialist, People TeamTeam
Viktoria Betin
Principal Scientist, Experimental ScienceTeam
Elina Locane
Senior Scientist, Computational ScienceTeam
Michael Robinson
Senior RA, Experimental ScienceTeam

42 more people are available in the full profile.

Premium access

Complete people profiles for Dyno Therapeutics

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of Dyno Therapeutics

3 dated milestones of Dyno Therapeutics across 3 years, from founding to its latest funding, stage changes and deals.

  1. Founded Dyno Therapeutics is founded.
  2. Funding First funding round of $9.0M.
  3. Funding Latest funding round, Series A, of $100.0M.

Competitors of Dyno Therapeutics

Dyno Therapeutics has 3 listed competitors in our database, 3 of them funded. They include BridgeBio, Spark Therapeutics and Alnylam.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
bridgebio.com2015Palo Alto, United States$434.2M
Therapeutics for genetic diseases are developed through targeted interventions.
sparktx.com2013Philadelphia, United States$82.8M822
Gene therapies for rare diseases including retinal dystrophies are developed.
alnylam.com2002Cambridge, United States$17M2,100
RNA interference-based therapeutics are developed for multiple disorders.
Premium access

Detailed competitors of Dyno Therapeutics

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Dyno Therapeutics

The website of Dyno Therapeutics (dynotx.com) receives about 14.4K visits a month and ranks #2,089,404 among all websites worldwide, #2,855 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    14.4K

    ▲ 35.5% vs previous month

  • Unique visitors
    4.8K

    per month

  • Global rank
    #2,089,404

    among all websites

  • Category rank
    #2,855

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with Dyno Therapeutics. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
sherlock.bio
100%
2.8K#4,929,420View details
cuebiopharma.com
97%
4.9K#7,063,180View details
ornatx.com
96%
4.4K#3,250,511View details
bioagilytix.com
94%
41.6K#919,146View details
dayzerodiagnostics.com
93%
1.4K#5,790,285View details
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
Premium access

All 18 similar websites and full traffic analytics for Dyno Therapeutics

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 18 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Genomics & Gene Therapy Platforms

3 companies that operate in the same segment as Dyno Therapeutics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Digital sequencing technology for cancer detection is developed.
2012Redwood City, California, United StatesUSD 557.5 MUSD 982.02 M4,867
Circulating tumor DNA is screened for early cancer detection.
2016Menlo Park, California, United StatesUSD 2 BUSD 147.17 M1,141
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Dyno Therapeutics

Premium access

Complete news archive for Dyno Therapeutics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Dyno Therapeutics

Dyno Therapeutics was founded in 2018 and raised its 1st funding round 2 years after it was founded.

Dyno Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.

Dyno Therapeutics is a funded company, having raised a total of $109M across 2 funding rounds to date. The company's 1st funding round was a Seed of $9M, raised on May 2020.

Dyno Therapeutics has 38 employees.

Founded in 2018 and based in Cambridge, United States, operations in the biotechnology sector are focused on AAV engineering through AI and data-driven methods. Vectors are developed for safe, targeted in vivo gene therapy delivery. Next-generation DNA synthesis of AAV capsids is combined with high-throughput sequencing and machine learning. Relationships between capsid sequences and functions are mapped, while vectors are optimized for enhanced therapeutic outcomes.

Dyno Therapeutics's top competitors include Spark Therapeutics, BridgeBio and Alnylam.

Dyno Therapeutics offers bCap 1, eCap 1, and Platform.

Dyno Therapeutics has 8 investors. Key investors include Andreessen Horowitz, Casdin Capital, Google Ventures, Obvious Ventures, and Lux Capital.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available